Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian...

|By:, SA News Editor

Oxigene (OXGN) says the European Medicines Agency has granted orphan drug status to its ovarian cancer treatment Zybrestat. Data from a Phase 2 trial testing the combination of Zybrestat and Roche's (RHHBY.OB) cancer drug Avastin - to treat advanced ovarian cancer - could be available in early 2014. If the results prove positive, it could provide the basis for a registration program. Shares +32% AH.